With FDA Hold Continuing, Idenix To Focus On NS5A Inhibitor And New Uridine Nucleosides
This article was originally published in The Pink Sheet Daily
Executive Summary
HCV-focused biotech tells J.P. Morgan conference audience it is making IDX719, its Phase II NS5A inhibitor, its lead program and hopes to start a non-exclusive combination trial with another company’s protease inhibitor this year.